{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:48:05Z","timestamp":1767145685020,"version":"build-2238731810"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalnutritionespen.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clnesp.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T20:33:09Z","timestamp":1521577989000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Should omega-3 fatty acids be used for adjuvant treatment of cancer cachexia?"],"prefix":"10.1016","volume":"25","author":[{"given":"Daryna Sergiyivna","family":"Lavriv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Miguel","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6056-8269","authenticated-orcid":false,"given":"Paula","family":"Ravasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2018.02.006_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ahj.2005.03.051","article-title":"Understanding omega-3\u2019s","volume":"151","author":"DeFilippis","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.clnesp.2018.02.006_bib2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.yexcr.2010.02.039","article-title":"Omega-3 fatty acids in cancer, the protectors of good and the killers of evil!?","volume":"316","author":"Gleissman","year":"2010","journal-title":"Exp Cell Res"},{"issue":"10","key":"10.1016\/j.clnesp.2018.02.006_bib3","first-page":"2289","article-title":"Essential fatty acids as functional components of foods \u2013 a review","volume":"51","author":"Kaur","year":"2014","journal-title":"J\u00a0Food Sci Technol"},{"issue":"4","key":"10.1016\/j.clnesp.2018.02.006_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0269216311418709","article-title":"A\u00a0systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project","volume":"26","author":"Ries","year":"2011","journal-title":"Palliat Med"},{"issue":"2","key":"10.1016\/j.clnesp.2018.02.006_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4102\/hsag.v13i2.279","article-title":"The role of long-chain polyunsaturated fatty acids in the treatment of cancer cachexia and tumour growth in patients with malignant diseases: a review","volume":"13","author":"Symington","year":"2008","journal-title":"Health SA Gesondheid"},{"issue":"Suppl.\u00a012","key":"10.1016\/j.clnesp.2018.02.006_bib6","first-page":"3427S","article-title":"(n-3) Fatty acids and cancer therapy","volume":"134","author":"Hardman","year":"2004","journal-title":"J\u00a0Nutr"},{"issue":"2","key":"10.1016\/j.clnesp.2018.02.006_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1503\/cmaj.071356","article-title":"The science behind dietary omega-3 fatty acids","volume":"178","author":"Surette","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.clnesp.2018.02.006_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1476-511X-8-33","article-title":"Are all n-3 polyunsaturated fatty acids created equal?","volume":"8","author":"Anderson","year":"2009","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnesp.2018.02.006_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.currproblcancer.2011.01.001","article-title":"Nutritional interventions for cancer-induced cachexia","volume":"35","author":"Gullett","year":"2011","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clnesp.2018.02.006_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12263-008-0078-1","article-title":"Fish oil and treatment of cancer cachexia","volume":"3","author":"Giacosa","year":"2008","journal-title":"Genes Nutr"},{"key":"10.1016\/j.clnesp.2018.02.006_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00520-009-0722-3","article-title":"Cancer cachexia: medical management","volume":"18","author":"Mantovani","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clnesp.2018.02.006_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11864-010-0127-z","article-title":"Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment","volume":"11","author":"Kumar","year":"2010","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.clnesp.2018.02.006_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.canlet.2008.03.044","article-title":"Multi-targeted therapy of cancer by Omega-3 fatty acids","volume":"269","author":"Berquin","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clnesp.2018.02.006_bib14","first-page":"1774","article-title":"Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment","volume":"140","author":"van der Meij","year":"2010","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.clnesp.2018.02.006_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ejcn.2011.214","article-title":"Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT","volume":"66","author":"van der Meij","year":"2012","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clnesp.2018.02.006_bib16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.bjc.6601620","article-title":"Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids","volume":"90","author":"Moses","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clnesp.2018.02.006_bib17","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2004.06.024","article-title":"An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central cancer treatment group and national cancer institute of Canada collaborative effort","volume":"22","author":"Jatoi","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clnesp.2018.02.006_bib18","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2005.04.5724","article-title":"Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia","volume":"24","author":"Fearon","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.clnesp.2018.02.006_bib19","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/01635581.2014.956253","article-title":"Introduction of an Omega-3 enriched oral supplementation for cancer patients close to the first chemotherapy: may it Be a factor for poor compliance?","volume":"66","author":"Pastore","year":"2014","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.clnesp.2018.02.006_bib20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/1472-6882-14-382","article-title":"Echium oil is not protective against weight loss in head and neck cancer patients undergoing curative radio(chemo)therapy: a randomised-controlled trial","volume":"14","author":"Pottel","year":"2014","journal-title":"BMC Compl Alternative Med"},{"issue":"1","key":"10.1016\/j.clnesp.2018.02.006_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1016\/j.clnesp.2018.02.006_bib22","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.clnesp.2018.02.006_bib23","series-title":"JPT GSe Higgins. Cochrane handbook for systematic reviews of interventions","year":"2011"},{"key":"10.1016\/j.clnesp.2018.02.006_bib24","first-page":"c869","volume":"vol. 340","author":"Moher","year":"2010"}],"updated-by":[{"DOI":"10.1016\/j.clnesp.2021.01.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000}}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457717304138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457717304138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T18:32:32Z","timestamp":1550946752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457717304138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":24,"alternative-id":["S2405457717304138"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2018.02.006","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should omega-3 fatty acids be used for adjuvant treatment of cancer cachexia?","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}